Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah A Forst

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Neurosurgery|November 5, 2025
Multi-Institutional Assessment of Circulating Cell-Free DNA in Cerebrospinal Fluid Facilitates Central Nervous System Lymphoma Diagnosis and Treatment InitiationBriana C Prager, Mihir Gupta, Timothy R West, et al.
Radiology|November 9, 2021
Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent GlioblastomaMohamed E El-Abtah, Michael R Wenke, Pratik Talati, et al.
Blood|February 28, 2019
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cellsPhilipp Karschnia, Justin T Jordan, Deborah A Forst, et al.
Neuro-Oncology Advances|June 16, 2021
MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastomaPratik Talati, Mohamed El-Abtah, Daniel Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2023
Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma PatientsK Ina Ly, Leland G Richardson, Mofei Liu, et al.
Neuro-Oncology|December 15, 2025
Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant GliomaGilbert Youssef, Elisa Aquilanti, Julie J Miller, et al.
Nature Communications|March 15, 2022
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomasPriscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, et al.
Neuro-Oncology|July 4, 2023
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cellsPhilipp Karschnia, Isabel C Arrillaga-Romany, April Eichler, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Neurosurgery|November 5, 2025
Multi-Institutional Assessment of Circulating Cell-Free DNA in Cerebrospinal Fluid Facilitates Central Nervous System Lymphoma Diagnosis and Treatment InitiationBriana C Prager, Mihir Gupta, Timothy R West, et al.
Radiology|November 9, 2021
Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent GlioblastomaMohamed E El-Abtah, Michael R Wenke, Pratik Talati, et al.
Blood|February 28, 2019
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cellsPhilipp Karschnia, Justin T Jordan, Deborah A Forst, et al.
Neuro-Oncology Advances|June 16, 2021
MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastomaPratik Talati, Mohamed El-Abtah, Daniel Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2023
Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma PatientsK Ina Ly, Leland G Richardson, Mofei Liu, et al.
Neuro-Oncology|December 15, 2025
Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant GliomaGilbert Youssef, Elisa Aquilanti, Julie J Miller, et al.
Nature Communications|March 15, 2022
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomasPriscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, et al.
Neuro-Oncology|July 4, 2023
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cellsPhilipp Karschnia, Isabel C Arrillaga-Romany, April Eichler, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.
Pageof 4